Effect of nuclear factor-κB and angiotensin Ⅱ receptor type 1 on the pathogenesis of rat non-alcoholic fatty liver disease

被引:2
|
作者
Dao-Yu Tan [1 ]
Hai-Yan Shi [2 ]
Chang-Ping Li [3 ]
Xiao-Ling Zhong [3 ]
Ming Kang [3 ]
机构
[1] Department of Basic Nursing, The Nursing College of Luzhou Medical College
[2] Department of Gastroenterology, People’s Hospital of Bazhong City
[3] Department of Gastroenterology, The Affiliated Hospital of Luzhou Medical College
关键词
Non-alcoholic fatty liver disease; Nuclear factor-κB; Angiotensin Ⅱ receptor type 1; Rats; Liver fibrosis;
D O I
暂无
中图分类号
R575.5 [肝代谢障碍];
学科分类号
1002 ; 100201 ;
摘要
AIM: To investigate the roles of nuclear factor(NF)-κB and angiotensin Ⅱ receptor type 1(AT1R) in the pathogenesis of non-alcoholic fatty liver disease(NAFLD).METHODS: Forty-two healthy adult male SpragueDawley rats were randomly divided into three groups:the control group(normal diet), the model group,and the intervention group(10 wk of a high-fat diet feeding, followed by an intraperitoneal injection of PDTC); 6 rats in each group were sacrificed at 6, 10,and 14 wk. After sacrifice, liver tissue was taken,paraffin sections of liver tissue specimens were prepared, hematoxylin and eosin(HE) staining was performed, and pathological changes in liver tissue(i.e., liver fibrosis) were observed by light microscopy.NF-κB expression in liver tissue was detected by immunohistochemistry, and the expression of AT1 R in the liver tissue was detected by reverse transcriptionpolymerase chain reaction(RT-PCR). The data are expressed as mean ± SD. A two-sample t test was used to compare the control group and the model group at different time points, paired t tests were used to compare the differences between the intervention group and the model group, and analysis of variance was used to compare the model group with the control group. Homogeneity of variance was analyzed with single factor analysis of variance. H variance analysis was used to compare the variance. P < 0.05 wasconsidered statistically significant.RESULTS: The NAFLD model was successful after 6wk and 10 wk. Liver fibrosis was found in four rats in the model group, but in only one rat in the intervention group at 14 wk. Liver steatosis, inflammation, and fibrosis were gradually increased throughout the model. In the intervention group, the body mass,rat liver index, serum lipid, and transaminase levels were not increased compared to the model group.In the model group, the degree of liver steatosis was increased at 6, 10, and 14 wk, and was significantly higher than in the control group(P < 0.01). In the model group, different degrees of liver cell necrosis were visible and small leaves, punctated inflammation,focal necrosis, and obvious ballooning degeneration were observed. Partial necrosis and confluent necrosis were observed. In the model group, liver inflammatory activity scores at 6, 10, and 14 wk were higher than in the control group(P < 0.01). Active inflammation in liver tissue in the intervention group was lower than in the model group(P < 0.05). HE staining showed liver fibrosis only at 14 wk in 4/6 rats in the model group and in 1/6 rats in the intervention group. NF-κB positive cells were stained yellow or ensemble yellow,and NF-κB was localized in the cytoplasm and/or nucleus. The model group showed NF-κB activation at6, 10, and 14 wk in liver cells; at the same time points,there were statistically significant differences in the control group(P < 0.01). Over time, NF-κB expression increased; this was statistically lower(P < 0.05) at14 weeks in the intervention group compared to the model group, but significantly increased(P < 0.05)compared with the control group; RT-PCR showed that AT1 R mRNA expression increased gradually in the model group; at 14 wk, the expression was significantly different compared with expression at 10 weeks as well as at 6 weeks(P < 0.05). In the model group, AT1 R mRNA expression was significantly higher than at the same time point in the control group(P <0.01).CONCLUSION: With increasing severity of NAFLD,NF-κB activity is enhanced, and the inhibition of NF-κB activity may reduce AT1 R mRNA expression in NAFLD.
引用
收藏
页码:5877 / 5883
页数:7
相关论文
共 50 条
  • [31] Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease
    Xiaoyan Li
    Hua Wang
    Cell & Bioscience, 10
  • [32] Pathogenesis of hepatocellular carcinoma development in non-alcoholic fatty liver disease
    Shetty K.
    Chen J.
    Shin J.-H.
    Jogunoori W.
    Mishra L.
    Current Hepatology Reports, 2015, 14 (2) : 119 - 127
  • [33] Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
    Teng, Tieshan
    Qiu, Shuai
    Zhao, Yiming
    Zhao, Siyuan
    Sun, Dequan
    Hou, Lingzhu
    Li, Yihang
    Zhou, Ke
    Yu, Xixi
    Yang, Changyong
    Li, Yanzhang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
  • [34] Telomerase: a key player in the pathogenesis of non-alcoholic fatty liver disease?
    Tang, Liang-Jie
    Rios, Rafael S.
    Zhang, Huai
    Byrne, Christopher D.
    Targher, Giovanni
    Zheng, Ming-Hua
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (07) : 811 - 819
  • [35] Oxysterols and redox signaling in the pathogenesis of non-alcoholic fatty liver disease
    Serviddio, G.
    Blonda, M.
    Bellanti, F.
    Villani, R.
    Iuliano, L.
    Vendemiale, G.
    FREE RADICAL RESEARCH, 2013, 47 (11) : 881 - 893
  • [36] Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact
    Caturano, Alfredo
    Acierno, Carlo
    Nevola, Riccardo
    Pafundi, Pia Clara
    Galiero, Raffaele
    Rinaldi, Luca
    Salvatore, Teresa
    Adinolfi, Luigi Elio
    Sasso, Ferdinando Carlo
    PROCESSES, 2021, 9 (01) : 1 - 18
  • [37] Non-alcoholic fatty liver disease from pathogenesis to management: an update
    Musso, G.
    Gambino, R.
    Cassader, M.
    OBESITY REVIEWS, 2010, 11 (06) : 430 - 445
  • [38] Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease
    Ma, Dae Won
    Ha, Joohun
    Yoon, Kyung Sik
    Kang, Insug
    Choi, Tae Gyu
    Kim, Sung Soo
    NUTRIENTS, 2023, 15 (09)
  • [39] The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    Zavos, Christos
    Tsiaousi, Eleni
    DIABETES OBESITY & METABOLISM, 2010, 12 (05): : 365 - 383
  • [40] Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease
    Li, Xiaoyan
    Wang, Hua
    CELL AND BIOSCIENCE, 2020, 10 (01):